1. 北京自然科学基金面上项目（7242018），循环肿瘤细胞小细胞三倍体亚型参与形成胶质瘤放化疗抵抗和不良预后的机制研究，2024.1-2026.12，主持，在研；

2. 首都卫生发展专项课题（2020-2-1075），小剂量放疗联合免疫佐剂治疗复发胶质母细胞瘤:一项单中心、开放、单臂临床研究，2020.7-2023.6，主持，结题；

3. 国家自然科学基金面上项目（81771309），干细胞参与血脑屏障内皮细胞拟态化和循环肿瘤细胞形成的分子机制研究，2018.1-2021.12，参加，结题；

4. 国家自然科学基金面上项目（81571632），基于多模态磁共振技术的胶质母细胞瘤复发风险评估研究，2016.1-2017.12，参加，结题；

1.     Zheng Y, Jiang H, Yang N, ShenS, Huang D, Jia L, Ling J, Xu L, Li M, Yu K, Ren X, Cui Y, Lan X, Lin S, Lin X.Glioma-derived ANXA1 suppresses the immune response to TLR3 ligands bypromoting an anti-inflammatory tumor microenvironment. Cell Mol Immunol. 2024, 21(1):47-59.

2.     Shen S, Cui Y, Li M, Yu K, ZhuQ, Zhang X, Shen W, Li H, Jiang H, Li M, Wang X, Zhao X, Ren X, Lin S.Toll-like receptor agonists promote the formation of tertiary lymphoidstructure and improve anti-glioma immunity. Neuro Oncol. 2025, 27(1):140-154.

3.     Ren X, Yang C, Li X, Cui Y,Wang Y, Sui D, Jiang Z, Lin S. Y-shaped branched ventriculo-peritoneal shuntfor adult multiloculated hydrocephalus. Chin Med J (Engl). 2022, 135(8):980-982.

4.     Yang C, Ren X, Cui Y, Jiang H,Li M, Yu K, Shen S, Li M, Zhang X, Zhao X, Zhu Q, Bu X, Lin S. New hopes andchallenges in targeted therapy and immunotherapy for primary central nervoussystem lymphoma. Front Immunol. 2025, 16:1438001.

5.     Li M, Wang J, Chen X, Dong G,Zhang W, Shen S, Jiang H, Yang C, Zhang X, Zhao X, Zhu Q, Li M, Cui Y, Ren X,Lin S. The sinuous, wave-like intratumoral-wall sign is a sensitive andspecific radiological biomarker for oligodendrogliomas. Eur Radiol. 2023, 33(6):4440-4452.

6.     Wang X, Jiang H, Li M, Zhang X,Li H, Li M, Ren X, Zhang S, Tong S, Liu A, Ren Q, Cui Y, Lin S. Corticalnonenhancing tumor infiltration: a predictive imaging biomarker for IDH-mutantglioma. J Neurosurg. 2025, 143(2):340-351.

7.     Li M, Huang W, Chen H, Jiang H,Yang C, Shen S, Cui Y, Dong G, Ren X, Lin S. T2/FLAIR Abnormity Could be theSign of Glioblastoma Dissemination. Front Neurol. 2022, 13:819216.

8.     Zhao X, Li M, Zhang G, Ren X,Yu S, Jiang H, Cui Y, Lin S. Extraventricular neurocytoma at the sellar region:Report of 8 cases and literature review. J Clin Neurosci. 2022, 99:379-386.

9.     Jiang H, Yu K, Cui Y, Ren X, LiM, Yang C, Zhao X, Zhu Q, Lin S. Combination of Immunotherapy and Radiotherapyfor Recurrent Malignant Gliomas: Results From a Prospective Study. FrontImmunol. 2021, 12:632547.

10.  Zhu Q, Jiang H, Cui Y, Ren X,Li M, Zhang X, Li H, Shen S, Li M, Lin S. Intratumoral calcification: not onlya diagnostic but also a prognostic indicator in oligodendrogliomas. Eur Radiol.2024, 34(6):3674-3685.

11.  Li M, Gao F, Ren X, Dong G,Chen H, Lin AY, Wang DD, Liu M, Lin PP, Shen S, Jiang H, Yang C, Zhang X, ZhaoX, Zhu Q, Li M, Cui Y, Lin S. Nonhematogenic circulating aneuploid cells conferinferior prognosis and therapeutic resistance in gliomas. Cancer Sci. 2022, 113(10):3535-3546.

12.  Ren X, Lin S, Wang Z, Luo L,Jiang Z, Sui D, Bi Z, Cui Y, Jia W, Zhang Y, Yu L, Chen S. Clinical,radiological, and pathological features of 24 atypical intracranial epidermoidcysts. J Neurosurg. 2012, 116(3):611-21.

13.  Jiang H, Cui Y, Liu X, Ren X,Lin S. Patient-Specific Resection Strategy of Glioblastoma Multiforme: ChoiceBased on a Preoperative Scoring Scale. Ann Surg Oncol. 2017, 24(7):2006-2014.

14.  Jiang H, Yu K, Cui Y, Ren X, LiM, Zhang G, Yang C, Zhao X, Zhu Q, Lin S. Differential Predictors and ClinicalImplications Associated With Long-Term Survivors in IDH Wildtype and MutantGlioblastoma. Front Oncol. 2021, 11:632663.

15.  Li H, Huang H, Zhang X, Wang Y,Ren X, Cui Y, Sui D, Lin S, Jiang Z, Zhang G. Postoperative Long-TermIndependence Among the Elderly With Meningiomas: Function Evolution,Determinant Identification, and Prediction Model Development. Front Oncol. 2021,11:639259.

16.  Cui Y, Zeng W, Jiang H, Ren X,Lin S, Fan Y, Liu Y, Zhao J. Higher Cho/NAA Ratio in Postoperative PeritumoralEdema Zone Is Associated With Earlier Recurrence of Glioblastoma. Front Neurol.2020, 11:592155.

17.  Zhu Q, Shen S, Yang C, Li M,Zhang X, Li H, Zhao X, Li M, Cui Y, Ren X, Lin S. A prognostic estimation modelbased on mRNA-sequence data for patients with oligodendroglioma. Front Neurol.2022, 13:1074593.

18.  Liu J, Hu S, Jiang H, Cui Y.Case report: Temozolomide induced hypermutation indicates an unfavorableresponse to immunotherapy in patient with gliomas. Front Immunol. 2024, 15:1369972.

19.  Li M, Ren X, Chen X, Wang J,Shen S, Jiang H, Yang C, Zhao X, Zhu Q, Cui Y, Lin S. Combining hyperintenseFLAIR rim and radiological features in identifying IDH mutant 1p/19qnon-codeleted lower-grade glioma. Eur Radiol. 2022, 32(6):3869-3879.

20.  Li M, Dong G, Zhang W, Ren X,Jiang H, Yang C, Zhao X, Zhu Q, Li M, Chen H, Yu K, Cui Y, Song L. CombiningMGMT promoter pyrosequencing and protein expression to optimize prognosisstratification in glioblastoma. Cancer Sci. 2021, 112(9):3699-3710.

21.  Jiang H, Cui Y, Liu X, Ren X,Li M, Lin S. Proliferation-dominant high-grade astrocytoma: survival benefitassociated with extensive resection of FLAIR abnormality region. J Neurosurg.2019, 132(4):998-1005.

22.  Jiang H, Yu K, Li M, Cui Y, RenX, Yang C, Zhao X, Lin S. Classification of Progression Patterns inGlioblastoma: Analysis of Predictive Factors and Clinical Implications. FrontOncol. 2020, 10:590648.

23.  Yang C, Cui Y, Ren X, Li M, YuK, Shen S, Jiang H, Li M, Zhang X, Zhao X, Zhu Q, Lin S. Orelabrutinib CombinedWith Lenalidomide and Immunochemotherapy for Relapsed/Refractory PrimaryCentral Nervous System Lymphoma: A Retrospective Analysis of Case Series. FrontOncol. 2022, 12:901797.

24.  Jiang H, Wang X, Chen X, ZhangS, Ren Q, Li M, Li M, Ren X, Lin S, Cui Y. Unraveling the heterogeneity of WHOgrade 4 gliomas: insights from clinical, imaging, and molecularcharacterization. Discov Oncol. 2025, 16(1):111.

25.  Ren X, Jiang H, Cui X, Cui Y,Ma J, Jiang Z, Sui D, Lin S. Co-polysomy of chromosome 1q and 19p predictsworse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of148 consecutive cases. Neuro Oncol. 2013, 15(9):1244-50.

26.  《中枢神经系统淋巴瘤》，参编，人民卫生出版社，2023-7.